Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (NCT07310901) titled 'A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With Obesity' on Dec. 16, 2025.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Double (Participant, Investigator).
Primary Sponsor: Corbus Pharmaceuticals Inc.
Condition:
Obese But Otherwise Healthy Participants
Intervention:
Drug: CRB-913
Recruitment Status: Recruiting
Phase: Phase 1
Date of First Enrollment: December 4, 2025
Target Sample Size: 252
Countries of Recruitment:
United States
To know ...